1. Lee HK. Mitochondrial dysfunction and insulin resistance: the contribution of dioxin-like substances. Diabetes Metab J 2011;35:207-15.
[CROSSREF] [PUBMED] [PMC]
2. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012;24:981-90.
[CROSSREF] [PUBMED] [PMC]
3. Lee HK, Cho YM, Kwak SH, Lim S, Park KS, Shim EB. Mitochondrial dysfunction and metabolic syndrome-looking for environmental factors. Biochim Biophys Acta 2010;1800:282-9.
[CROSSREF] [PUBMED]
4. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384-7.
[CROSSREF] [PUBMED]
5. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:446-52.
[CROSSREF] [PUBMED] [PMC]
6. Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017;13:629-46.
[CROSSREF] [PUBMED] [PMC]
7. Che R, Yuan Y, Huang S, Zhang A. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol 2014;306:F367-78.
[CROSSREF] [PUBMED]
8. Granata S, Dalla Gassa A, Bellin G, Lupo A, Zaza G. Transcriptomics: a step behind the comprehension of the polygenic influence on oxidative stress, immune deregulation, and mitochondrial dysfunction in chronic kidney disease. Biomed Res Int 2016;2016:9290857.
[CROSSREF] [PUBMED] [PMC]
9. Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013;24:1901-12.
[CROSSREF] [PUBMED] [PMC]
10. Gamboa JL, Billings FT 4th, Bojanowski MT, Gilliam LA, Yu C, Roshanravan B, et al. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep 2016;4:e12780.
[CROSSREF] [PUBMED] [PMC]
11. Granata S, Zaza G, Simone S, Villani G, Latorre D, Pontrelli P, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009;10:388.
[CROSSREF] [PUBMED] [PMC]
12. Zaza G, Granata S, Masola V, Rugiu C, Fantin F, Gesualdo L, et al. Downregulation of nuclear-encoded genes of oxidative metabolism in dialyzed chronic kidney disease patients. PLoS One 2013;8:e77847.
[CROSSREF] [PUBMED] [PMC]
13. Eirin A, Saad A, Tang H, Herrmann SM, Woollard JR, Lerman A, et al. Urinary mitochondrial DNA copy number identifies chronic renal injury in hypertensive patients. Hypertension 2016;68:401-10.
[CROSSREF] [PUBMED]
14. Mutsaers HA, Wilmer MJ, Reijnders D, Jansen J, van den Broek PH, Forkink M, et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta 2013;1832:142-50.
[CROSSREF] [PUBMED]
15. Nadal A, Quesada I, Tuduri E, Nogueiras R, Alonso-Magdalena P. Endocrine-disrupting chemicals and the regulation of energy balance. Nat Rev Endocrinol 2017;13:536-46.
[CROSSREF] [PUBMED]
16. Kim JT, Lee HK. Metabolic syndrome and the environmental pollutants from mitochondrial perspectives. Rev Endocr Metab Disord 2014;15:253-62.
[CROSSREF] [PUBMED]
17. Park WH, Kang S, Lee HK, Salihovic S, Bavel BV, Lind PM, et al. Relationships between serum-induced AhR bioactivity or mitochondrial inhibition and circulating polychlorinated biphenyls (PCBs). Sci Rep 2017;7:9383.
[CROSSREF] [PUBMED] [PMC]
18. Lee HK, Park WH, Kang YC, Kang S, Im S, Park S, et al. Serum biomarkers from cell-based assays for AhRL and MIS strongly predicted the future development of diabetes in a large community-based prospective study in Korea. Sci Rep 2020;10:6339.
[CROSSREF] [PUBMED] [PMC]
19. Kim JT, Kim SS, Jun DW, Hwang YH, Park WH, Pak YK, et al. Serum arylhydrocarbon receptor transactivating activity is elevated in type 2 diabetic patients with diabetic nephropathy. J Diabetes Investig 2013;4:483-91.
[CROSSREF] [PUBMED] [PMC]
20. Kim Y, Han BG. KoGES group. Cohort profile: the Korean Genome and Epidemiology Study (KoGES) Consortium. Int J Epidemiol 2017;46:e20.
[CROSSREF] [PUBMED]
21. Park WH, Jun DW, Kim JT, Jeong JH, Park H, Chang YS, et al. Novel cell-based assay reveals associations of circulating serum AhR-ligands with metabolic syndrome and mitochondrial dysfunction. Biofactors 2013;39:494-504.
[CROSSREF] [PUBMED]
22. Vondracek J, Pencikova K, Neca J, Ciganek M, Grycova A, Dvorak Z, et al. Assessment of the aryl hydrocarbon receptor-mediated activities of polycyclic aromatic hydrocarbons in a human cell-based reporter gene assay. Environ Pollut 2017;220(Pt A):307-16.
[CROSSREF] [PUBMED]
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
[CROSSREF] [PUBMED] [PMC]
24. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
[PUBMED]
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
[CROSSREF] [PUBMED]
26. Kolachalama VB, Shashar M, Alousi F, Shivanna S, Rijal K, Belghasem ME, et al. Uremic solute-aryl hydrocarbon receptor-tissue factor axis associates with thrombosis after vascular injury in humans. J Am Soc Nephrol 2018;29:1063-72.
[CROSSREF] [PUBMED] [PMC]
27. Shinde R, McGaha TL. The aryl hydrocarbon receptor: connecting immunity to the microenvironment. Trends Immunol 2018;39:1005-20.
[CROSSREF] [PUBMED] [PMC]
28. Brinkmann V, Ale-Agha N, Haendeler J, Ventura N. The aryl hydrocarbon receptor (AhR) in the aging process: another puzzling role for this highly conserved transcription factor. Front Physiol 2020;10:1561.
[CROSSREF] [PUBMED] [PMC]
29. Stanifer JW, Stapleton HM, Souma T, Wittmer A, Zhao X, Boulware LE. Perfluorinated chemicals as emerging environmental threats to kidney health: a scoping review. Clin J Am Soc Nephrol 2018;13:1479-92.
[PUBMED] [PMC]
30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
31. Avilla MN, Malecki KM, Hahn ME, Wilson RH, Bradfield CA. The Ah receptor: adaptive metabolism, ligand diversity, and the Xenokine Model. Chem Res Toxicol 2020;33:860-79.
[CROSSREF] [PUBMED] [PMC]
32. Kataria A, Trasande L, Trachtman H. The effects of environmental chemicals on renal function. Nat Rev Nephrol 2015;11:610-25.
[CROSSREF] [PUBMED] [PMC]